Overview

A Phase II Study Evaluating SB-751689 in Post-Menopausal Women With Osteoporosis.

Status:
Terminated
Trial end date:
2008-12-26
Target enrollment:
Participant gender:
Summary
This is a 12 month study designed to evaluate the safety and effectiveness of SB-751689 in the treatment of osteoporosis in post-menopausal women, in comparison with 2 active comparators and placebo.
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Alendronate
Teriparatide